Pulmonary Arterial Hypertension Market Size, Share & Trends Report

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class, By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-2-68038-855-8
  • Number of Pages: 150
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2023
  • Industry: Healthcare

Market Segmentation

  • Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
    • Endothelin Receptor Antagonists (ERAs)
    • PDE-5 Inhibitors
    • Prostacyclin and Prostacyclin Analogs
    • SGC Stimulators
  • Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
    • Branded
    • Generics
  • Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    • Oral
    • Intravenous/ subcutaneous
    • Inhalational
  • Pulmonary Arterial Hypertension Regional Outlook (Revenue, USD Million, 2018 - 2030)
    • North America
      • North America Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030) (Average Selling Price in USD ) (Volume in Million Units)
        • Endothelin Receptor Antagonists (ERAs)
        • PDE-5 Inhibitors
        • Prostacyclin and Prostacyclin Analogs
        • SGC Stimulators
      • North America Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
        • Branded
        • Generics
      • North AmericaPulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
        • Oral
        • Intravenous/ subcutaneous
        • Inhalational
      • U.S.
        • U.S. Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • U.S. Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • U.S. Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • Canada
        • Canada Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Canada Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Canada Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
    • Europe
      • Europe Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030) (Average Selling Price in USD ) (Volume in Million Units)
        • Endothelin Receptor Antagonists (ERAs)
        • PDE-5 Inhibitors
        • Prostacyclin and Prostacyclin Analogs
        • SGC Stimulators
      • Europe Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
        • Branded
        • Generics
      • Europe Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
        • Oral
        • Intravenous/ subcutaneous
        • Inhalational
      • Germany
        • Germany Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Germany Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Germany Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • UK
        • UK Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • UK Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • UK Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • France
        • France Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • France Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • France Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • Italy
        • Italy Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Italy Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Italy Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • Spain
        • Spain Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Spain Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Spain Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • Denmark
        • Denmark Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Denmark Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Denmark Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • Sweden
        • Sweden Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Sweden Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Sweden Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • Norway
        • Norway Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Norway Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Norway Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
    • Asia Pacific
      • Asia Pacific Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030) (Average Selling Price in USD ) (Volume in Million Units)
        • Endothelin Receptor Antagonists (ERAs)
        • PDE-5 Inhibitors
        • Prostacyclin and Prostacyclin Analogs
        • SGC Stimulators
      • Asia Pacific Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
        • Branded
        • Generics
      • Asia Pacific Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
        • Oral
        • Intravenous/ subcutaneous
        • Inhalational
      • China
        • China Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • China Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • China Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • India
        • India Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • India Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • India Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • Japan
        • Japan Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Japan Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Japan Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • Australia
        • Australia Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Australia Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Australia Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • South Korea
        • South Korea Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • South Korea Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • South Korea Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • Thailand
        • Thailand Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Thailand Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Thailand Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
    • Latin America
      • Latin America Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030) (Average Selling Price in USD ) (Volume in Million Units)
        • Endothelin Receptor Antagonists (ERAs)
        • PDE-5 Inhibitors
        • Prostacyclin and Prostacyclin Analogs
        • SGC Stimulators
      • Latin America Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
        • Branded
        • Generics
      • Latin America Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
        • Oral
        • Intravenous/ subcutaneous
        • Inhalational
      • Brazil
        • Brazil Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Brazil Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Brazil Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • Mexico
        • Mexico Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Mexico Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Mexico Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • Argentina
        • Argentina Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Argentina Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Argentina Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
    • MEA
      • MEA Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030) (Average Selling Price in USD ) (Volume in Million Units)
        • Endothelin Receptor Antagonists (ERAs)
        • PDE-5 Inhibitors
        • Prostacyclin and Prostacyclin Analogs
        • SGC Stimulators
      • MEA Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
        • Branded
        • Generics
      • MEA Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
        • Oral
        • Intravenous/ subcutaneous
        • Inhalational
      • South Africa
        • South Africa Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • South Africa Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • South Africa Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • Saudi Arabia
        • South Africa Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • South Africa Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • South Africa Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • UAE
        • UAE Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • UAE Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • UAE Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational
      • Kuwait
        • Kuwait Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
          • Endothelin Receptor Antagonists (ERAs)
          • PDE-5 Inhibitors
          • Prostacyclin and Prostacyclin Analogs
          • SGC Stimulators
        • Kuwait Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Branded
          • Generics
        • Kuwait Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
          • Oral
          • Intravenous/ subcutaneous
          • Inhalational

Pulmonary Arterial Hypertension Market Dynamics

Drivers: Incidents Of Pulmonary Arterial Hypertension (PAH)

The global prevalence of PAH is very low, which is around 15 to 50 cases per million, hence, it is classified as a rare disorder. Cumulatively, the cases of PAH are in the range of 100,000 to 200,000 per year. However, in the past few years, the prevalence of this disorder has risen due to risk factors like sedentary lifestyle, HIV, smoking, alcohol/tobacco consumption, and other idiopathic conditions. PAH may occur in association with various diseases, such as lung and cardiac diseases. Frequently observed underlying causes include connective tissue disorders, congenital heart disorders, coronary artery disorder, blood clots, and high blood pressure.

Growing Geriatric Population

The presence of a large population over 60 years, which has lower immunity levels and is prone to PAH and associated diseases, is a high impact-rendering driver for the growth of the PAH market over the forecast period. Although the onset age for PAH is 45 years, it is frequently observed to occur in populations above 60 years of age. This population is expected to avail the best possible treatments, increasing the life span. The chart below forecasts the number of geriatric patients over the next 6 years who may form a routine target group contributing toward the increasing demand for PAH drugs.

Restraints: Patent Expiration Of Key Molecules

Loss of exclusivity has a direct impact on the market of branded pharmaceutical products. Also, with the Drug Price Competition and Patent Term Restoration Act, of 1984, informally known as the Hatch-Waxman Act, the development of generic drugs is encouraged, which impacts the sale of branded molecules. The license expiry of some blockbuster drugs is making way for generic drug penetration. The increased sales of generic drugs adversely affect the overall revenue generation of the market since it is 70 to 80 percent cheaper as compared to branded drugs. Cutting-edge therapies are developed for treating PAH. Therefore, the future of the pulmonary arterial hypertension market is presumed to be brighter in the years to come.

What Does This Report Include?

This section will provide insights into the contents included in this pulmonary arterial hypertension market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Pulmonary arterial hypertension market qualitative analysis

  • Industry overview

  • Industry trends

  • Market drivers and restraints

  • Market size

  • Growth prospects

  • Porter’s analysis

  • PESTEL analysis

  • Key market opportunities prioritized

  • Competitive landscape

    • Company overview

    • Financial performance

    • Product benchmarking

    • Latest strategic developments

Pulmonary arterial hypertension market quantitative analysis

  • Market size, estimates, and forecast from 2018 to 2030

  • Market estimates and forecast for product segments up to 2030

  • Regional market size and forecast for product segments up to 2030

  • Market estimates and forecast for application segments up to 2030

  • Regional market size and forecast for application segments up to 2030

  • Company financial performance

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon